LLY250117P310000
- 0.20
- 0.000.00%
Eli Lilly and Co Newsroom
Eli Lilly and Co's Q4 performance expectations are slightly below, with the 2025 revenue guidance exceeding expectations.
Eli Lilly and Co expects a revenue growth of 45% year-on-year for the fourth quarter to 13.5 billion dollars, slightly below the market expectation of 14 billion dollars. However, the company expects annual revenue between 58 billion to 61 billion dollars, which is higher than the market expectation of 58.72 billion dollars.
On the first day of the JPM Medical Conference, pharmaceutical giants are announcing new strategies. Could the mergers and acquisitions in Biomedical begin in 2025?
In 2025, the Biomedical mergers and acquisitions will begin.
The three major U.S. stock indexes experienced mixed results, with the China Concept Index rising by 2.1% and Eli Lilly and Co falling by 6.6%.
On January 15th, Gelonghui reported that the three major U.S. stock indices closed mixed, with the Nasdaq down 0.23%, the S&P 500 Index up 0.11%, and the Dow Jones up 0.52%. Most large Technology stocks declined, with Tesla, NVIDIA, and Netflix each dropping over 1%. Meta fell by more than 2%, as the company plans to lay off 5% of low-performing employees. Eli Lilly and Co closed down 6.6%, marking its worst single-day performance since March 2021, as the company forecasts weak sales for weight-loss drugs in the fourth quarter. The Nasdaq China Golden Dragon Index increased by 2.1%, with China Concept Stocks rising broadly, including Xpeng Autos up over 6%, JD.com up over 4%, and Kingsoft Cloud and Bilibili each up over 3%.
Eli Lilly and Co Options Spot-On: On January 14th, 109.58K Contracts Were Traded, With 326.59K Open Interest
On January 14th ET, $Eli Lilly and Co(LLY.US)$ had active options trading, with a total trading volume of 109.58K options for the day, of which put options accounted for 40.72% of the total
Trending Stocks Today | Eterna Therapeutics Surges 66.76%
January 14th - US stocks trending in regular trading hours.Gainers: $Eterna Therapeutics(ERNA.US)$ soars 66.76% to $0.52 with a turnover of $401.2 million. $Firefly Neuroscience(AIFF.US)$ surges 67.21
Eli Lilly And Co. To Present At J.P. Morgan Healthcare Conference; Webcast At 5:15 PM ET
The demand for weight loss drugs has dragged down Eli Lilly and Co's Q4 performance, which may fall short of expectations, while revenue guidance exceeds expectations, and the stock price once dropped nearly 9%｜Earnings Reports insights.
Eli Lilly and Co released a performance report indicating that the Q4 revenue forecast fell short of expectations. The company explained that the demand for weight loss drugs grew less than anticipated, and that the end-of-year inventory level was insufficient, affecting performance. This marks the second consecutive quarter that the company has failed to meet sales targets due to forecasting errors. Analysts say that the market has very high expectations for its growth, leaving Eli Lilly and Co with almost no room for mistakes. Although Eli Lilly and Co optimistically forecasts revenue to reach between 58 billion and 61 billion dollars in 2025, surpassing market expectations, the stock price fell nearly 9% in early trading on Tuesday.
ETF Earnings: Biggest Weeks for Major Funds as Holdings Report
Sector Update: Health Care Stocks Fall Tuesday Afternoon
Jefferies Adjusts Price Target on Eli Lilly to $996 From $994
Sector Update: Health Care
Top Midday Decliners
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
Eli Lilly and Co's revenue forecast for 2024 did not meet Analyst expectations, causing the stock price to plummet.
① Eli Lilly and Co expects global revenue of approximately 45 billion USD in 2024, an increase of 32%, but lower than the expected 45.5 billion USD; ② Eli Lilly and Co's global revenue for the fourth quarter of last year is expected to be 13.5 billion USD, an increase of 45%, but lower than the expected 14 billion USD.
Update: Eli Lilly Shares Fall After Downbeat Q4 Revenue Guidance
US Equity Indexes Fall as Investors Evaluate Easing in Wholesale Price Inflation
Hims & Hers in Focus as Eli Lilly GLP-1 Sales Disappoint
Stocks Search for Firm Footing After Cooler Producer Inflation Data
Lilly's Zepbound and Mounjaro Sales Miss Estimates Again. The Wobble's Looking Serious.